CRANBURY, N.J., Oct. 16, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that an oral presentation and 3 posters related to its investigational pharmacological chaperones will be included at two upcoming scientific meetings. American Society of Nephrology (ASN) Kidney Week 2012 October 30-November 4, 2012 in San Diego, CA Long Term Effects of Migalastat HCl on Fabry Nephropathy. - Germain D.P., Giugliani R., Pastores G., Nicholls K., Shankar S., Schiffmann R., Hughes D., Mehta A., Waldek S., Jovanovic A., Bragat A., Sitaraman S., Sniukiene V., Winkler R., Boudes P.
- Oral Abstract Session: Saturday, November 3, 2012, 4:30-6:30pm PDT (Dominique P. Germain, U. of Versailles)
- Poster: November 7, 2012, 3:15-4:15 pm PST (Dominique P. Germain, U. of Versailles)
- Poster: November 8, 2012, 3:15-4:15 pm PST (David Warnock, U. of Alabama-Birmingham)
- Poster: November 8, 2012, 3:15-4:15 pm PST (Raphael Schiffmann, Baylor Research Institute)
CONTACT: Investors/Media: Sara Pellegrino firstname.lastname@example.org (609) 662-5044